AeroLEF (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia for patients experiencing acute pain episodes. AeroLEF is in development for the treatment of moderate to severe pain, including cancer pain.
Mechanism of action:
AeroLEF is developed to offer a simple and non-invasive route of administration, rapid onset of action, sustained effect and self-titratable dosing for the treatment of acute and breakthrough pain, conditions that are common in cancer patients and underserved by existing fixed-dose delivery technologies. Using AeroLEF, patients can identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.